Circulating microRNAs modulating glycolysis as non-invasive prognostic biomarkers of HNSCC

Identifier:  imarina:7238099

Handle: https://hdl.handle.net/20.500.11797/imarina7238099

Authors:  Avilés-Jurado, FX; Muñoz, C; Meler, C; Flores, JC; Gumà, J; Benaiges, E; Mora, J; Camacho, M; León, X; Vilaseca, I; Terra, X

Abstract:
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature. Background: The identification of prognostic non-invasive biomarkers is a priority for cancer patients’ care. Circulating microRNA (miRNAs) have been described in numerous human malignancies as diagnostic, prognostic, and therapeutic cancer biomarkers. The aim of our study was to analyze the expression profile of a set of miRNAs, involved in the modulation of the glycolytic pathway, as prognostic factors in human head and neck squamous cell carcinomas (HNSCC). Methods: Serum samples of 54 patients with untreated HNSCC were obtained at the time of diagnosis. The prognostic value of circulating miR-26b, miR-124, miR-155 and miR-375 was evaluated towards disease-free survival. Results: We found that there were optimal miRNAs cut-off values for lower risk of recurrence in HNSCC patients. Kaplan–Meier curves showed that higher levels of miR-26b and lower levels of miR-155 were associated with better disease-free survival rates. In the multivariate analysis, patients with serum miR-26b > 0.062 and miR-155 < 0.159 presented more than 2.9 times lower risk of poor outcome. Conclusion: Our results suggest that two miRNAs that modulate the glycolytic pathway, miR-26b and miR-155, are independently associated with the risk of recurrence in patients with HNSCC. The overall results in this study supports the evidence that the glucose homeostasis may be a target to improve the outcomes for patients with HNSCC. Level of evidence: Individual retrospective cohort study (2b).